Bg pattern

SUNLENCA 300 mg FILM-COATED TABLETS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use SUNLENCA 300 mg FILM-COATED TABLETS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Sunlenca 300 mg Film-Coated Tablets

lenacapavir

This medicine is subject to additional monitoring, which will help to quickly identify new safety information. You can help by reporting any side effects you may get. The last section of this leaflet includes information on how to report side effects.

Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the Package Leaflet

  1. What is Sunlenca and what is it used for
  2. What you need to know before you take Sunlenca
  3. How to take Sunlenca
  4. Possible side effects
  5. Storage of Sunlenca
  6. Contents of the pack and other information

1. What is Sunlenca and what is it used for

Sunlenca contains the active substance lenacapavir. It is an antiretroviral medicine known as a capsid inhibitor.

Sunlenca is used in combination with other antiretroviral medicinesto treat human immunodeficiency virus type 1 (HIV-1) infection, the virus that causes acquired immune deficiency syndrome (AIDS).

It is used to treat HIV-1 infection in adults with limited treatment options (for example, when other antiretroviral medicines are not effective enough or are not suitable).

Treatment with Sunlenca in combination with other antiretrovirals reduces the amount of HIV in the body. This improves the function of the immune system (the body's natural defence system) and reduces the risk of developing illnesses associated with HIV infection.

Your doctor will tell you to take Sunlenca tablets before you are given Sunlenca injections for the first time.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you take Sunlenca

Do not take Sunlenca

  • If you are allergic to lenacapavir or any of the other ingredients of this medicine (listed in section 6).
  • If you are taking any of the following medicines:
    • rifampicin, used to treat some bacterial infections such as tuberculosis
    • carbamazepine, phenytoin, used to prevent seizures
    • St John's Wort (Hypericum perforatum), a herbal medicine used for depression and anxiety

?If you think this applies to you, do not take Sunlenca and tell your doctor immediately.

Warnings and precautions

Tell your doctor before taking Sunlenca

  • Tell your doctor or pharmacist if you have or have ever had severe liver disease or if tests have shown liver problems. Your doctor will carefully consider whether to treat you with Sunlenca or not.

While you are taking Sunlenca

Once you start taking Sunlenca, be aware of:

  • Signs of inflammation or infection

?If you notice any of these symptoms, tell your doctor immediately.For more information, see section 4, Possible side effects.

Children and adolescents

Do not give this medicine to children under 18 years of age. The use of Sunlenca in patients under 18 years of age has not been studied yet, so it is not known how safe and effective the medicine is in this age group.

Other medicines and Sunlenca

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Sunlenca may interact with other medicines. This can prevent Sunlenca or other medicines from working properly or make side effects worse. In some cases, your doctor may need to adjust the dose or check your blood levels.

Medicines that must not be taken with Sunlenca:

  • rifampicin, used to treat some bacterial infections such as tuberculosis
  • carbamazepine, phenytoin, used to prevent seizures
  • St John's Wort (Hypericum perforatum), a herbal medicine used for depression and anxiety

?If you are taking any of these medicines, do not take Sunlenca and tell your doctor immediately.

Tell your doctor especially if you are taking:

  • antibiotics that contain:
    • rifabutin
  • anti-epileptics, used to treat epilepsy and prevent seizures (fits), that contain:
    • oxcarbazepine or phenobarbital
  • medicines used to treat HIV, that contain:
    • atazanavir/cobicistat, efavirenz, nevirapine, tipranavir/ritonavir or etravirine
  • medicines used to treat migraine headaches, that contain:
    • dihydroergotamine or ergotamine
  • medicines used to treat impotence and pulmonary hypertension, that contain:
    • sildenafil or tadalafil
  • medicines used to treat impotence, that contain:
    • vardenafil
  • corticosteroids (also known as “steroids”) given by mouth or by injection, used to treat allergies, inflammatory bowel diseases and various other diseases that involve inflammation in the body, that contain:
    • dexamethasone or hydrocortisone/cortisone
  • medicines used to lower cholesterol, that contain:
    • lovastatin or simvastatin
  • anti-arrhythmics used to treat heart problems, that contain:
    • digoxin
  • medicines used to help you sleep, that contain:
    • midazolam or triazolam
  • anticoagulants used to prevent and treat blood clots, that contain:
    • rivaroxaban, dabigatran or edoxaban

?Tell your doctor if you are taking any of these medicinesor if you start taking any of these medicines during treatment with Sunlenca. Do not stop your treatment without talking to your doctor.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

As a precaution, you should avoid using Sunlenca during pregnancy unless your doctor tells you otherwise.

It is recommended that women with HIV-1 infection do not breast-feed their babies, as HIV-1 infection can be passed to the baby through breast milk. If you are breast-feeding or think you might want to breast-feed, talk to your doctor as soon as possible.

Driving and using machines

Sunlenca is not expected to affect your ability to drive or use machines.

Sunlenca contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per tablet, which is essentially “sodium-free”.

3. How to take Sunlenca

Sunlenca is used in combination with other antiretroviral medicinesto treat HIV infection. Your doctor will tell you which other medicines you should take to treat HIV infection and when you should take them.

Treatment with Sunlenca starts with taking tablets by mouth, followed by injections given by your doctor or nurse, as described below.

Talk to your doctor before taking the tablets.Your doctor will tell you when to start taking the tablets and when to schedule your appointment to receive the first injections.

Day 1 of treatment:

  • Two tablets by mouth. These can be taken with or without food.

Day 2 of treatment:

  • Two tablets by mouth. These can be taken with or without food.

Day 8 of treatment:

  • One tablet by mouth. This can be taken with or without food.

Day 15 of treatment:

  • Two injections into the abdomen (belly) given at the same time by your doctor or nurse.

Every 6 months:

  • Two injections into the abdomen given at the same time by your doctor or nurse.

If you take more Sunlenca than you should

Contact your doctor or pharmacist immediately for advice. If you take more than the recommended dose of Sunlenca, you may be at greater risk of experiencing side effects (see section 4, Possible side effects).

It is important that you do not miss a dose of Sunlenca tablets.

If you miss a dose of tablets,contact your doctor or pharmacist immediately.

If you vomitwithin 3 hours of taking Sunlenca tablets, contact your doctor immediately and take another two tablets. If you vomit more than 3 hours after taking Sunlenca, you do not need to take any more tablets until your next scheduled dose, either as tablets or injection.

If you miss an injection of Sunlenca

  • It is important that you attend your scheduled appointments every 6 months to receive the Sunlenca injections. This will help to control your HIV infection and prevent your illness from getting worse.
  • If you think you will not be able to attend your appointment to receive the injections, call your doctor as soon as possible to discuss your treatment options.

Do not stop taking Sunlenca

Do not stop taking Sunlenca tablets without talking to your doctor. Stopping Sunlenca may seriously affect the effectiveness of future treatments for HIV.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects: tell a doctor immediately

  • Any signs of inflammation or infection. In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections (infections that occur in people with a weak immune system), signs and symptoms of inflammation due to previous infections may occur soon after starting treatment for HIV. It is thought that these symptoms are due to an improvement in the body's immune response, which enables it to fight off infections that may have been present without obvious symptoms.
  • Autoimmune disorders, where the immune system attacks the body's healthy tissues, can also occur after you start taking medicines for HIV infection. Autoimmune disorders can occur many months after starting treatment. Be aware of any symptoms of infection or other symptoms, such as:
    • muscle weakness
    • weakness of the body that starts in the hands and feet and moves towards the trunk
    • palpitations, tremor or hyperactivity

?If you notice any of these symptoms or any symptoms of inflammation or infection, tell your doctor immediately.

Common side effects

(may affect up to 1 in 10 people)

  • Nausea

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Sunlenca

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after {CAD}. The expiry date refers to the last day of the month shown.

This medicine does not require any special storage conditions. Keep the blister in the outer carton in order to protect from moisture.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6. Contents of the pack and other information

What Sunlenca contains

The active substance is lenacapavir. Each tablet contains lenacapavir sodium equivalent to 300 mg of lenacapavir.

The other ingredients are

Tablet core

mannitol (E421), microcrystalline cellulose (E460), sodium croscarmellose (E468), copovidone, magnesium stearate (E572), poloxamer (see section 2, Sunlenca contains sodium).

Tablet coating

polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol (E1521), talc (E553b), yellow iron oxide (E172), black iron oxide (E172), red iron oxide (E172).

Appearance of Sunlenca and pack contents

Sunlenca film-coated tablets are beige, capsule-shaped, film-coated tablets marked with “GSI” on one face of the tablet and “62L” on the other face of the tablet. Sunlenca is available in a blister pack of 5 film-coated tablets. The blister pack is packaged in an aluminium paper pouch. The aluminium paper pouch contains a silica gel desiccant that should remain in the pouch to help protect the tablets. The silica gel is packaged in a separate sachet or container and should not be swallowed.

Marketing authorisation holder

Gilead Sciences Ireland UC

Carrigtohill

County Cork, T45 DP77

Ireland

Manufacturer

Gilead Sciences Ireland UC

IDA Business & Technology Park

Carrigtohill

County Cork

Ireland

You can ask for more information about this medicine from the local representative of the marketing authorisation holder:

België/Belgique/Belgien

Gilead Sciences Belgium SRL-BV

Tél/Tel: + 32 (0) 24 01 35 50

Lietuva

Gilead Sciences Poland Sp. z o.o.

Tel.: + 48 22 262 8702

????????

Gilead Sciences Ireland UC

???.: + 353 (0) 1 686 1888

Luxembourg/Luxemburg

Gilead Sciences Belgium SRL-BV

Tél/Tel: + 32 (0) 24 01 35 50

Ceská republika

Gilead Sciences s.r.o.

Tel: + 420 910 871 986

Magyarország

Gilead Sciences Ireland UC

Tel.: + 353 (0) 1 686 1888

Danmark

Gilead Sciences Sweden AB

Tlf: + 46 (0) 8 5057 1849

Malta

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Deutschland

Gilead Sciences GmbH

Tel: + 49 (0) 89 899890-0

Nederland

Gilead Sciences Netherlands B.V.

Tel: + 31 (0) 20 718 36 98

Eesti

Gilead Sciences Poland Sp. z o.o.

Tel.: +48 22 262 8702

Norge

Gilead Sciences Sweden AB

Tlf: + 46 (0) 8 5057 1849

Ελλ?δα

Gilead Sciences Ελλ?ς Μ.ΕΠΕ.

Τηλ: + 30 210 8930 100

Österreich

Gilead Sciences GesmbH

Tel: + 43 1 260 830

España

Gilead Sciences, S.L.

Tel: + 34 91 378 98 30

Polska

Gilead Sciences Poland Sp. z o.o.

Tel.: + 48 22 262 8702

France

Gilead Sciences

Tél: + 33 (0) 1 46 09 41 00

Portugal

Gilead Sciences, Lda.

Tel: + 351 21 7928790

Hrvatska

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

România

Gilead Sciences (GSR) S.R.L.

Tel: + 40 31 631 18 00

Ireland

Gilead Sciences Ireland UC

Tel: + 353 (0) 214 825 999

Slovenija

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Ísland

Gilead Sciences Sweden AB

Sími: + 46 (0) 8 5057 1849

Slovenská republika

Gilead Sciences Slovakia s.r.o.

Tel: + 421 232 121 210

Italia

Gilead Sciences S.r.l.

Tel: + 39 02 439201

Suomi/Finland

Gilead Sciences Sweden AB

Puh/Tel: + 46 (0) 8 5057 1849

Κ?προς

Gilead Sciences Ελλ?ς Μ.ΕΠΕ.

Τηλ: + 30 210 8930 100

Sverige

Gilead Sciences Sweden AB

Tel: + 46 (0) 8 5057 1849

Latvija

Gilead Sciences Poland Sp. z o.o.

Tel.: + 48 22 262 8702

United Kingdom (Northern Ireland)

Gilead Sciences Ireland UC

Tel: + 44 (0) 8000 113 700

Date of last revision of this leaflet:

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.

Online doctors for SUNLENCA 300 mg FILM-COATED TABLETS

Discuss questions about SUNLENCA 300 mg FILM-COATED TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
0.0 (0)
Doctor

Daniel Cichi

Family medicine 24 years exp.

Dr Daniel Cichi is a family medicine doctor with over 20 years of clinical experience. He provides online consultations for adults, supporting patients with acute symptoms, chronic conditions, and everyday health concerns that require timely medical guidance.

His background includes work in emergency care, ambulance services, and family medicine, which allows him to assess symptoms quickly, identify warning signs, and help patients choose the safest next steps – whether that means home care, treatment adjustment, or in-person evaluation.

Patients commonly consult Dr Daniel Cichi for:

  • acute symptoms: fever, infections, flu-like illness, cough, sore throat, shortness of breath;
  • chest discomfort, palpitations, dizziness, fatigue, and blood pressure concerns;
  • digestive problems: abdominal pain, nausea, diarrhoea, constipation, reflux;
  • muscle, joint, and back pain, minor injuries, post-traumatic symptoms;
  • chronic conditions: hypertension, diabetes, high cholesterol, thyroid disorders;
  • review and interpretation of lab tests, imaging reports, and medical documents;
  • medication review and treatment adjustment;
  • medical advice while travelling or living abroad;
  • second opinions and guidance on whether in-person care is needed.
Dr Cichi’s consultations are structured and practical. He focuses on clear explanations, risk assessment, and actionable recommendations, helping patients understand their symptoms and make informed decisions about their health.
Camera Book a video appointment
€55

Frequently Asked Questions

Is a prescription required for SUNLENCA 300 mg FILM-COATED TABLETS?
SUNLENCA 300 mg FILM-COATED TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in SUNLENCA 300 mg FILM-COATED TABLETS?
The active ingredient in SUNLENCA 300 mg FILM-COATED TABLETS is lenacapavir. This information helps identify medicines with the same composition but different brand names.
Who manufactures SUNLENCA 300 mg FILM-COATED TABLETS?
SUNLENCA 300 mg FILM-COATED TABLETS is manufactured by Gilead Sciences Ireland Unlimited Company. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of SUNLENCA 300 mg FILM-COATED TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether SUNLENCA 300 mg FILM-COATED TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to SUNLENCA 300 mg FILM-COATED TABLETS?
Other medicines with the same active substance (lenacapavir) include SUNLENCA 464 mg INJECTABLE SOLUTION, CELSENTRI 150 mg FILM-COATED TABLETS, CELSENTRI 300 MG FILM-COATED TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media